Serum N-terminal midfragment vs. intact osteocalcin immunoradiometric assay as markers for bone turnover and bone loss in hemodialysis patients

Biomedicine and Pharmacotherapy

Volumn 57, Issue 2, 2003, Pages 98-104

  Nagasue, K ^a   Inaba, M ^b   Okuno, S ^a   Kitatani, K ^a   Imanishi, Y ^a   Ishimura, E ^b   Miki, T ^b   Kim, M ^a   Nishizawa, Y ^b  

^a Shirasagi Hospital   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone marker; Chronic renal failure; Osteocalcin

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; DEOXYPYRIDINOLINE; MARKER; OSTEOCALCIN; PARATHYROID HORMONE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINO TERMINAL SEQUENCE; ARTICLE; BONE METABOLISM; BONE TURNOVER; CONTROLLED STUDY; CORRELATION ANALYSIS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; IMMUNORADIOMETRIC ASSAY; IMMUNOREACTIVITY; INCUBATION TIME; INTERMETHOD COMPARISON; MALE; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; ROOM TEMPERATURE; SERUM;

EID: 0038772211     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(02)00344-X     Document Type: Article

References (29)

1. Price P.A., Otsuka A.S., Poser J.W., Kristaponis I., Raman N. Characterization of a gamma-carboxyglutamic acid-containing protein from bone. Proc Natl Acad Sci USA. 73:1976;1447-1451.
2. Hauschk P.V., Lian J.B., Gallop P.M. Direct identification of the calcium-binding amino acid, carboxyglutamate, in mineralized tissue. Proc Natl Acad Sci USA. 72:1975;3925-3929.
3. Lian J.B., Gundberg C.M. Osteocalcin: biochemical considerations and clinical applications. Clin Orthop. 226:1988;267-291.
4. Price P.A. Osteocalcin. Peck W.A. Bone and mineral research. 1983;157-190 Excerpta Medica, Princeton.
5. Morishita T., Nomura M., Hanaoka M., Saruta T., Matsuo T., Tsukamoto Y. A new assay method that detects only intact osteocalcin. Two-step non-invasive diagnosis to predict adynamic bone disease in haemodialysed patients. Nephrol Dial Tranplant. 15:2000;659-667.
6. Gundberg C.M., Weinstein R.S. Multiple immunoreactive forms of osteocalcin in uremic serum. J Clin Invest. 77:1986;1762-1767.
7. Garnero P., Grimaux M., Segun P., Delmas P. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res. 9:1994;255-264.
8. Nakatsuka K., Miki T., Nishizawa Y., Tabata T., Inoue T., Morii H., et al. Circulating bone gla protein in end-stage renal disease determined by newly developed two-site immunoradiometric assay. Contrib Nephrol. 90:1991;147-154.
9. Delmas P.D., Christiansen C., Mann K.G., Price P.A. Bone Gla protein (osteocalcin) assay standardization report. J Bone Miner Res. 5:1990;5-11.
10. Takahashi M., Kushida K., Nagano A., Inoue T. Comparison of the analytical and clinical performance characteristics of an N-MID versus an intact osteocalcin immunoradiometric assay. Clin Chim Acta. 294:2000;67-76.
11. Rosenquist C., Bonde M., Qvist P. A competitive immunoassay (ELISA) for the detection of N-terminal-related osteocalcin; improved stability of osteocalcin in serum. J Bone Miner Res. 1:(Suppl 1):1994;S140.
12. Rosenquist C., Qvist P., Bjarnason N., Christiansen C. Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem. 41:1995;1439-1445.
13. Ishimura E., Okuno S., Kim M., Yamamoto T., Izumotani T., Otoshi T., et al. Increasing body fat mass in the first year of hemodialysis. J Am Soc Nephrol. 12:2001;1921-1926.
14. Inaba M., Morii H., Katsumata T., Goto H., Ishimura E., Kawagishi T., et al. Hyperparathyroidism is augmented by ovariectomy in Nagase analbuminemic rats. J Nutr. 130:2000;1543-1547.
15. Inaba M., Nishizawa Y., Mita K., Kumeda Y., Emoto M., Kawagishi T., et al. Poor glycemic control impairs the response of biochemical parameters of bone formation and resorption to exogenous 1,25-dihydroxyvitamin D3 in patients with type 2 diabetes. Osteoporosis Int. 9:1999;525-531.
16. Kumeda Y., Inaba M., Tahara H., Kurioka Y., Ishikawa T., Morii H., et al. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism. J Clin Endocrinol Metab. 85:2000;4157-4161.
17. Inaba M., Terada M., Nishizawa Y., Shioi A., Ishimura E., Otani S., et al. Protective effect of an aldose reductase inhibitor against bone loss in galactose-fed rats: possible involvement of the polyol pathway in bone metabolism. Metabolism. 48:1999;904-909.
18. Lepage R., Roy L., Brossard J.H., Rousseau L., Dorais C., Lazure C., et al. A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem. 44:1998;805-809.
19. Arnaud C.D., Pun K.K. Metabolism and assay of parathyroid hormone. Coe F.L., Favus M.J. Disorders of bone and mineral metabolism. 1992;107-122 Raven Press, New York.
20. Gomes Jr B., Ardakani S., Ju J., Jenkins D., Cerelli M.J., Daniloff G.Y., et al. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem. 41:1995;1560-1566.
21. Nemoto R., Nakamura I., Nishijima Y., Shiobara K., Shimizu M., Takehara T., et al. Serum pyridinoline crosslinks as markers of tumor-induced bone resorption. Br J Urol. 80:1997;274-280.
22. Furumitsu Y., Inaba M., Yukioka K., Kumeda Y., Azuma Y., Ohta T., et al. Levels of serum and synovial fluid pyridinium crosslinks in patients with rheumatoid arthritis. J Rheumatol. 27:2000;64-70.
23. Urena P., Ferreira A., Kung V.T., Morieux C., Simon P., Ang K.S., et al. Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients. J Bone Miner Res. 10:1995;932-939.
24. Inaba M., Ishikawa T., Imanishi Y., Ishimura E., Nakatsuka K., Morii H., et al. Pathophysiology and diagnosis of primary hyperparathyroidism-strategy for asymptomatic primary hyperparathyroidism. Biomed Pharmacother. 54:(Suppl 1):2000;7s-11s.
25. Parisien M., Mellish R.W., Silverberg S.J., Shane E., Lindsay R., Bilezikian J.P., et al. Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular strut analysis. J Bone Miner Res. 7:1992;913-919.
26. Urena P., De Vernejoul M.C. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int. 55:1999;2141-2156.
27. Nakayama K., Fukumoto S., Takeda S., Takeuchi Y., Ishikawa T., Miura M., et al. Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. J Clin Endocrinol Metab. 81:1996;607-611.
28. Garnero P., Grimaux M., Seguin P., Delmas P.D. Characterization of immunoreactive forms of human osteocalcin with a human specific two-site immunoradiometric assay. J Bone Miner Res. 7:1992;1389-1398.
29. Inaba M., Nagasue K., Okuna S., Veda M., Kumeda Y., Imanishi Y., et al. Impaired secretion of parathyroid hormone, but not refractoriness of osteoblast, is a major mechanism of low bone turnover in hemodialyzed patients with diabetes mellitus. Am J Kidney Dis. 39:2002;1261-1269.